SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001104659-23-100614
Filing Date
2023-09-14
Accepted
2023-09-14 06:19:21
Documents
13
Period of Report
2023-09-13
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2326019d1_8k.htm   iXBRL 8-K 29975
2 EXHIBIT 99.1 tm2326019d1_ex99-1.htm EX-99.1 10755
  Complete submission text file 0001104659-23-100614.txt   219245

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA fwbi-20230913.xsd EX-101.SCH 3027
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE fwbi-20230913_lab.xml EX-101.LAB 34240
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE fwbi-20230913_pre.xml EX-101.PRE 22367
7 EXTRACTED XBRL INSTANCE DOCUMENT tm2326019d1_8k_htm.xml XML 3318
Mailing Address 777 YAMATO ROAD SUITE 502 BOCA RATON FL 33431
Business Address 777 YAMATO ROAD SUITE 502 BOCA RATON FL 33431 561-589-7020
First Wave BioPharma, Inc. (Filer) CIK: 0001604191 (see all company filings)

IRS No.: 464993860 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37853 | Film No.: 231253996
SIC: 2834 Pharmaceutical Preparations